课题基金 / 基金详情

PHASE II STUDY OF IV ADMINISTERED TIRAPAZAMINE PLUS CISPLATIN IN NSCLC

PHASE II STUDY OF IV ADMINISTERED TIRAPAZAMINE PLUS CISPLATIN IN NSCLC
静脉注射替拉扎明联合顺铂治疗 NSCLC 的 II 期研究
批准号：
5218404
负责人：
CHANDRA BELANI
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5218404
关键词：
antineoplastics cis platinum compound clinical research combination chemotherapy drug screening /evaluation human subject human therapy evaluation intravenous administration neoplasm /cancer chemotherapy neoplasm /cancer pharmacology nonsmall cell lung cancer

项目摘要

项目成果

CHANDRA BELANI的其他基金

相关文献

中文摘要
翻译
这是一项II期多中心研究，IV替拉帕嗪加顺铂
英文摘要
This is a phase II, multi-center study of IV Tirapazamine plus Cisplatin in patients with non-small cell lung cancer (NSCLC) to estimate the rate of objective tumor response to tirapazamine when administered intravenously in combination with cisplatin; to estimate time to disease progression; and to assess the safety of the combined treatment regimen in this population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: A PHASE I STUDY IN ADVANCED SOLID MALIGNANCIES (NCI 7967)
CLINICAL TRIAL: PI & PHARMACOKINETIC STUDY OF DRUG FOR SOLID TUMORS & LYMPHOMAS
CLINICAL TRIAL: PI &PHARMACOKINETIC SINGLE AGENT STUDY OF DRUG IN PTS W ADV MALI
Phase I Clinical Trials of Novel Anticancer Agents